Functional significance of erythropoietin in renal cell carcinoma

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Morais, Christudas ^a   Johnson, David W ^a   Vesey, David A ^a   Gobe, Glenda C ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CISPLATIN; DAUNORUBICIN; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; HYPOXIA INDUCIBLE FACTOR; INTERLEUKIN 2; VINBLASTINE; VON HIPPEL LINDAU PROTEIN;

BREAST CANCER; CARCINOGENESIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEAD AND NECK CANCER; HORMONE ACTION; HUMAN; KIDNEY CARCINOMA; METASTASIS; MOLECULAR PATHOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECURRENT CANCER; REVIEW; THROMBOSIS; VASCULAR DISEASE;

ANEMIA; ANIMALS; CARCINOMA, RENAL CELL; ERYTHROPOIETIN; HEMATINICS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; KIDNEY NEOPLASMS; RECEPTORS, ERYTHROPOIETIN; RECOMBINANT PROTEINS; RISK FACTORS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84872104379     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-14     Document Type: Review

References (100)

1. Eble J, Sauter G, Epstein J, Sesterhenn I. Pathology and genetics. Tumours of the urinary system and male genital organs 2001, Lyon: IARC Press.
2. Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z. 2004 WHO classification of the renal tumors of the adults. Eur Urol 2006, 49(5):798-805. 10.1016/j.eururo.2005.11.035, 16442207.
3. Curti BD. Renal cell carcinoma. JAMA 2004, 292(1):97-100. 10.1001/jama.292.1.97, 15238597.
4. Seizinger BR, Rouleau GA, Ozelius LJ, Lane AH, Farmer GE, Lamiell JM, Haines J, Yuen JW, Collins D, Majoor-Krakauer D, et al. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 1988, 332(6161):268-269. 10.1038/332268a0, 2894613.
5. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004, 22(24):4991-5004. 10.1200/JCO.2004.05.061, 15611513.
6. Clark PE. The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. Kidney Int 2009, 76(9):939-945. 10.1038/ki.2009.296, 2963106, 19657325.
7. Ohh M, Kaelin WG. VHL and kidney cancer. Methods Mol Biol 2003, 222:167-183.
8. Arai E, Kanai Y. Genetic and epigenetic alterations during renal carcinogenesis. Int J Clin Exp Pathol 2010, 4(1):58-73. 3016104, 21228928.
9. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994, 91(21):9700-9704. 10.1073/pnas.91.21.9700, 44884, 7937876.
10. Kondo K, Yao M, Yoshida M, Kishida T, Shuin T, Miura T, Moriyama M, Kobayashi K, Sakai N, Kaneko S, et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosomes Cancer 2002, 34(1):58-68. 10.1002/gcc.10054, 11921283.
11. Gong K, Zhang N, Zhang Z, Na Y. Coexpression of erythopoietin and erythopoietin receptor in sporadic clear cell renal cell carcinoma. Cancer Biol Ther 2006, 5(6):582-585. 10.4161/cbt.5.6.2709, 16627979.
12. Prowse AH, Webster AR, Richards FM, Richard S, Olschwang S, Resche F, Affara NA, Maher ER. Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors. Am J Hum Genet 1997, 60(4):765-771. 1712486, 9106522.
13. Brauch H, Weirich G, Brieger J, Glavac D, Rodl H, Eichinger M, Feurer M, Weidt E, Puranakanitstha C, Neuhaus C, et al. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res 2000, 60(7):1942-1948.
14. Hes FJ, Hoppener JW, Lips CJ. Clinical review 155: Pheochromocytoma in Von Hippel-Lindau disease. J Clin Endocrinol Metab 2003, 88(3):969-974. 10.1210/jc.2002-021466, 12629069.
15. Jonasch E, Futreal PA, Davis IJ, Bailey ST, Kim WY, Brugarolas J, Giaccia AJ, Kurban G, Pause A, Frydman J, et al. State of the science: an update on renal cell carcinoma. Mol Cancer Res 2012, 10(7):859-880. 10.1158/1541-7786.MCR-12-0117, 3399969, 22638109.
16. Procopio G, Verzoni E, Iacovelli R, Guadalupi V, Gelsomino F, Buzzoni R. Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience. Expert Rev Anticancer Ther 2011, 11(11):1631-1640. 10.1586/era.11.154, 22050012.
17. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995, 92(12):5510-5514. 10.1073/pnas.92.12.5510, 41725, 7539918.
18. Kaluz S, Kaluzova M, Stanbridge EJ. Does inhibition of degradation of hypoxia-inducible factor (HIF) alpha always lead to activation of HIF? Lessons learnt from the effect of proteasomal inhibition on HIF activity. J Cell Biochem 2008, 104(2):536-544. 10.1002/jcb.21644, 18059036.
19. Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999, 15:551-578. 10.1146/annurev.cellbio.15.1.551, 10611972.
20. Huang LE, Bunn HF. Hypoxia-inducible factor and its biomedical relevance. J Biol Chem 2003, 278(22):19575-19578. 10.1074/jbc.R200030200, 12639949.
21. Maynard MA, Ohh M. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer. Am J Nephrol 2004, 24(1):1-13. 10.1159/000075346, 14654728.
22. Maynard MA, Qi H, Chung J, Lee EH, Kondo Y, Hara S, Conaway RC, Conaway JW, Ohh M. Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. J Biol Chem 2003, 278(13):11032-11040. 10.1074/jbc.M208681200, 12538644.
23. Baldewijns MM, Van VIJ, Vermeulen PB, Soetekouw PM, Van EM, De BAP. VHL and HIF signalling in renal cell carcinogenesis. J Pathol 2010, 221(2):125-138. 10.1002/path.2689, 20225241.
24. Stebbins CE, Kaelin WG, Pavletich NP. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 1999, 284(5413):455-461. 10.1126/science.284.5413.455, 10205047.
25. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, Kaelin WG. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000, 2(7):423-427. 10.1038/35017054, 10878807.
26. Kaelin WG. The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing. Cold Spring Harb Symp Quant Biol 2005, 70:159-166. 10.1101/sqb.2005.70.001, 16869749.
27. Tanimoto K, Makino Y, Pereira T, Poellinger L. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J 2000, 19(16):4298-4309. 10.1093/emboj/19.16.4298, 302039, 10944113.
28. Ohh M. Ubiquitin pathway in VHL cancer syndrome. Neoplasia 2006, 8(8):623-629. 10.1593/neo.06442, 1601944, 16925945.
29. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399(6733):271-275. 10.1038/20459, 10353251.
30. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001, 292(5516):468-472. 10.1126/science.1059796, 11292861.
31. Salceda S, Caro J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 1997, 272(36):22642-22647. 10.1074/jbc.272.36.22642, 9278421.
32. Huang LE, Gu J, Schau M, Bunn HF. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1998, 95(14):7987-7992. 10.1073/pnas.95.14.7987, 20916, 9653127.
33. Rankin EB, Tomaszewski JE, Haase VH. Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor. Cancer Res 2006, 66(5):2576-2583. 10.1158/0008-5472.CAN-05-3241, 3514875, 16510575.
34. Rad FH, Ulusakarya A, Gad S, Sibony M, Juin F, Richard S, Machover D, Uzan G. Novel somatic mutations of the VHL gene in an erythropoietin-producing renal carcinoma associated with secondary polycythemia and elevated circulating endothelial progenitor cells. Am J Hematol 2008, 83(2):155-158. 10.1002/ajh.21019, 17696210.
35. Wiesener MS, Eckardt KU. Erythropoietin, tumours and the von Hippel-Lindau gene: towards identification of mechanisms and dysfunction of oxygen sensing. Nephrol Dial Transplant 2002, 17(3):356-359. 10.1093/ndt/17.3.356, 11865075.
36. Wiesener MS, Seyfarth M, Warnecke C, Jurgensen JS, Rosenberger C, Morgan NV, Maher ER, Frei U, Eckardt KU. Paraneoplastic erythrocytosis associated with an inactivating point mutation of the von Hippel-Lindau gene in a renal cell carcinoma. Blood 2002, 99(10):3562-3565. 10.1182/blood.V99.10.3562, 11986208.
37. Wiesener MS, Munchenhagen P, Glaser M, Sobottka BA, Knaup KX, Jozefowski K, Jurgensen JS, Roigas J, Warnecke C, Grone HJ, et al. Erythropoietin gene expression in renal carcinoma is considerably more frequent than paraneoplastic polycythemia. Int J Cancer 2007, 121(11):2434-2442. 10.1002/ijc.22961, 17640059.
38. Lacombe C, Mayeux P. The molecular biology of erythropoietin. Nephrol Dial Transplant 1999, 14(Suppl 2):22-28.
39. Fisher JW, Koury S, Ducey T, Mendel S. Erythropoietin production by interstitial cells of hypoxic monkey kidneys. Br J Haematol 1996, 95(1):27-32. 10.1046/j.1365-2141.1996.d01-1864.x, 8857934.
40. Koury ST, Bondurant MC, Koury MJ. Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood 1988, 71(2):524-527.
41. Chateauvieux S, Grigorakaki C, Morceau F, Dicato M, Diederich M. Erythropoietin, erythropoiesis and beyond. Biochem Pharmacol 2011, 82(10):1291-1303. 10.1016/j.bcp.2011.06.045, 21782802.
42. Lacombe C, Da SJL, Bruneval P, Fournier JG, Wendling F, Casadevall N, Camilleri JP, Bariety J, Varet B, Tambourin P. Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J Clin Invest 1988, 81(2):620-623. 10.1172/JCI113363, 329613, 3339134.
43. Eckardt KU. Erythropoietin production in liver and kidneys. Curr Opin Nephrol Hypertens 1996, 5(1):28-34. 10.1097/00041552-199601000-00007, 8834159.
44. Zanjani ED, Ascensao JL, McGlave PB, Banisadre M, Ash RC. Studies on the liver to kidney switch of erythropoietin production. J Clin Invest 1981, 67(4):1183-1188. 10.1172/JCI110133, 370680, 7204572.
45. Lacombe C, Da SJL, Bruneval P, Casadevall N, Camilleri JP, Bariety J, Tambourin P, Varet B. Erythropoietin: sites of synthesis and regulation of secretion. Am J Kidney Dis 1991, 18(4 Suppl 1):14-19.
46. Farrell F, Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 2004, 9(Suppl 5):18-30.
47. Westenfelder C, Baranowski RL. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 2000, 58(2):647-657. 10.1046/j.1523-1755.2000.00211.x, 10916088.
48. Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell'Era P, Nico B, Roncali L, Dammacco F. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999, 93(8):2627-2636.
49. Li J, Vesey DA, Johnson DW, Gobe G. Erythropoietin reduces cisplatin-induced apoptosis in renal carcinoma cells via a PKC dependent pathway. Cancer Biol Ther 2007, 6(12):1944-1950. 10.4161/cbt.6.12.4975, 18075299.
50. Michael A, Politi E, Havranek E, Corbishley C, Karapanagiotou L, Anderson C, Relph K, Syrigos KN, Pandha H. Prognostic significance of erythropoietin expression in human renal cell carcinoma. BJU Int 2007, 100(2):291-294. 10.1111/j.1464-410X.2007.06978.x, 17617137.
51. Mulcahy L. The erythropoietin receptor. Semin Oncol 2001, 28(2 Suppl 8):19-23.
52. Witthuhn BA, Quelle FW, Silvennoinen O, Yi T, Tang B, Miura O, Ihle JN. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 1993, 74(2):227-236. 10.1016/0092-8674(93)90414-L, 8343951.
53. Frank SJ. Receptor dimerization in GH and erythropoietin action-it takes two to tango, but how?. Endocrinology 2002, 143(1):2-10. 10.1210/en.143.1.2, 11751584.
54. Bao H, Jacobs-Helber SM, Lawson AE, Penta K, Wickrema A, Sawyer ST. Protein kinase B (c-Akt), phosphatidylinositol 3-kinase, and STAT5 are activated by erythropoietin (EPO) in HCD57 erythroid cells but are constitutively active in an EPO-independent, apoptosis-resistant subclone (HCD57-SREI cells). Blood 1999, 93(11):3757-3773.
55. Wojchowski DM, Gregory RC, Miller CP, Pandit AK, Pircher TJ. Signal transduction in the erythropoietin receptor system. Exp Cell Res 1999, 253(1):143-156. 10.1006/excr.1999.4673, 10579919.
56. Gong K, Zhang N, Zhang K, Na Y. The relationship of erythropoietin overexpression with von Hippel-Lindau tumour suppressor gene mutations between hypoxia-inducible factor-1alpha and -2alpha in sporadic clear cell renal carcinoma. Int J Mol Med 2010, 26(6):907-912.
57. Ljungberg B, Rasmuson T, Grankvist K. Erythropoietin in renal cell carcinoma: evaluation of its usefulness as a tumor marker. Eur Urol 1992, 21(2):160-163.
58. Gross AJ, Wolff M, Fandrey J, Miersch WD, Dieckmann KP, Jelkmann W. Prevalence of paraneoplastic erythropoietin production by renal cell carcinomas. Clin Investig 1994, 72(5):337-340.
59. Clark D, Kersting R, Rojiani AM. Erythropoietin immunolocalization in renal cell carcinoma. Mod Pathol 1998, 11(1):24-28.
60. Lee YS, Vortmeyer AO, Lubensky IA, Vogel TW, Ikejiri B, Ferlicot S, Benoit G, Giraud S, Oldfield EH, Linehan WM, et al. Coexpression of erythropoietin and erythropoietin receptor in von Hippel-Lindau disease-associated renal cysts and renal cell carcinoma. Clin Cancer Res 2005, 11(3):1059-1064.
61. Butnor KJ, Nicholson AG, Allred DC, Zander DS, Henderson DW, Barrios R, Haque AK, Allen TC, Killen DE, Cagle PT. Expression of renal cell carcinoma-associated markers erythropoietin, CD10, and renal cell carcinoma marker in diffuse malignant mesothelioma and metastatic renal cell carcinoma. Arch Pathol Lab Med 2006, 130(6):823-827.
62. Papworth K, Bergh A, Grankvist K, Ljungberg B, Rasmuson T. Expression of erythropoietin and its receptor in human renal cell carcinoma. Tumour Biol 2009, 30(2):86-92. 10.1159/000216844, 19407488.
63. Murphy GP, Kenny GM, Mirand EA. Erythropoietin levels in patients with renal tumors or cysts. Cancer 1970, 26(1):191-194. 10.1002/1097-0142(197007)26:1<191::AID-CNCR2820260124>3.0.CO;2-S, 5424529.
64. Noguchi Y, Goto T, Yufu Y, Uike N, Hasegawa Y, Fukuda T, Jimi A, Funakoshi A. Gene expression of erythropoietin in renal cell carcinoma. Intern Med 1999, 38(12):991-994. 10.2169/internalmedicine.38.991, 10628941.
65. Nielsen OJ, Jespersen FF, Hilden M. Erythropoietin-induced secondary polycythemia in a patient with a renal cell carcinoma. A case report. Apmis 1988, 96(8):688-694.
66. Hanada T, Mimata H, Ohno H, Nasu N, Nakagawa M, Nomura Y. Erythropoietin-producing renal cell carcinoma arising from acquired cystic disease of the kidney. Int J Urol 1998, 5(5):493-494. discussion 495, 10.1111/j.1442-2042.1998.tb00397.x, 9781442.
67. Toyama K, Fujiyama N, Suzuki H, Chen TP, Tamaoki N, Ueyama Y. Erythropoietin levels in the course of a patient with erythropoietin-producing renal cell carcinoma and transplantation of this tumor in nude mice. Blood 1979, 54(1):245-253.
68. Burk JR, Lertora JJ, Martinez IR, Fisher JW. Renal cell carcinoma with erythrocytosis and elevated erythropoietic stimulatory activity. South Med J 1977, 70(8):955-958. 10.1097/00007611-197708000-00017, 578014.
69. Rubins J. Metastatic renal cell carcinoma: response to treatment with human recombinant erythropoietin. Ann Intern Med 1995, 122(9):676-677.
70. Sungur C. Renal cell carcinoma and erythropoietin. Ann Intern Med 1995, 123(9):732-733.
71. Talmon GA. Pure erythropoiesis in clear cell renal cell carcinoma. Int J Surg Pathol 2010, 18(6):544-546.
72. Murphy GP, Brendler H, Mirand EA. Erythropoietin release from renal cell carcinomas grown in tissue culture. Res Commun Chem Pathol Pharmacol 1970, 1(5):617-626.
73. Sherwood JB, Goldwasser E. Erythropoietin production by human renal carcinoma cells in culture. Endocrinology 1976, 99(2):504-510. 10.1210/endo-99-2-504, 986292.
74. Shouval D, Sherwood JB. Production of erythropoietin by an established human renal carcinoma cell line: in vitro and in vivo studies. Adv Exp Med Biol 1988, 241:319-328.
75. Sherwood JB, Shouval D. Continuous production of erythropoietin by an established human renal carcinoma cell line: development of the cell line. Proc Natl Acad Sci USA 1986, 83(1):165-169. 10.1073/pnas.83.1.165, 322812, 3455754.
76. Hagiwara M, Chen IL, McGonigle R, Beckman B, Kasten FH, Fisher JW. Erythropoietin production in a primary culture of human renal carcinoma cells maintained in nude mice. Blood 1984, 63(4):828-835.
77. Katsuoka Y, McGonigle R, Rege AB, Beckman B, Fisher JW. Erythropoietin production in human renal carcinoma cells passaged in nude mice and in tissue culture. Gann 1983, 74(4):534-541.
78. Okabe T, Urabe A, Kato T, Chiba S, Takaku F. Production of erythropoietin-like activity by human renal and hepatic carcinomas in cell culture. Cancer 1985, 55(9):1918-1923. 10.1002/1097-0142(19850501)55:9<1918::AID-CNCR2820550915>3.0.CO;2-9, 4038914.
79. Sytkowski AJ, Richie JP, Bicknell KA. New human renal carcinoma cell line established from a patient with erythrocytosis. Cancer Res 1983, 43(3):1415-1419.
80. Magera JS, Leibovich BC, Lohse CM, Sengupta S, Cheville JC, Kwon ED, Blute ML. Association of abnormal preoperative laboratory values with survival after radical nephrectomy for clinically confined clear cell renal cell carcinoma. Urology 2008, 71(2):278-282. 10.1016/j.urology.2007.08.048, 2789389, 18308103.
81. Nseyo UO, Williams PD, Murphy GP. Clinical significance of erythropoietin levels in renal carcinoma. Urology 1986, 28(4):301-306. 10.1016/0090-4295(86)90011-7, 3765240.
82. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996, 335(12):865-875. 10.1056/NEJM199609193351207, 8778606.
83. Da SJL, Lacombe C, Bruneval P, Casadevall N, Leporrier M, Camilleri JP, Bariety J, Tambourin P, Varet B. Tumor cells are the site of erythropoietin synthesis in human renal cancers associated with polycythemia. Blood 1990, 75(3):577-582.
84. Blay JY, Pallard M, Ravaud A. Serum VEGF is an independent prognostic factor in patients with metastatic renal cell carcinoma treated with IL-1 and/or IFN: analysis of the Crecy trial. Proc Am Ass Clin Oncol (Abstr) 1997, 18..
85. Lissoni P, Rovelli F, Baiocco N, Tangini G, Fumagalli L. A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone. Anticancer Res 2001, 21(1B):777-779.
86. Morere JF, Bouillet T, Piperno-Neumann S, Tourani JM, Brunet A, Hennebelle F, Bareau JL. Treatment of advanced kidney cancer using recombinant erythropoietin. Prog Urol 1997, 7(3):399-402.
87. Janik JE, Sznol M, Urba WJ, Figlin R, Bukowski RM, Fyfe G, Pierce WC, Belldegrun A, Sharfman WH, Smith JW, et al. Erythropoietin production. A potential marker for interleukin-2/interferon-responsive tumors. Cancer 1993, 72(9):2656-2659. 10.1002/1097-0142(19931101)72:9<2656::AID-CNCR2820720922>3.0.CO;2-A, 8402486.
88. Carvalho G, Lefaucheur C, Cherbonnier C, Metivier D, Chapel A, Pallardy M, Bourgeade MF, Charpentier B, Hirsch F, Kroemer G. Chemosensitization by erythropoietin through inhibition of the NF-kappaB rescue pathway. Oncogene 2005, 24(5):737-745. 10.1038/sj.onc.1208205, 15580299.
89. Miyajima J, Imai Y, Nakao M, Noda S, Itoh K. Higher susceptibility of erythropoietin-producing renal cell carcinomas to lysis by lymphokine-activated killer cells. J Immunother Emphasis Tumor Immunol 1996, 19(6):399-404. 10.1097/00002371-199611000-00003, 9041458.
90. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003, 4(8):459-460. 10.1016/S1470-2045(03)01163-X, 12901958.
91. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003, 362(9392):1255-1260. 10.1016/S0140-6736(03)14567-9, 14575968.
92. Information for Healthcare Professionals: Erythropoiesis Stimulating Agents (ESA) [Aranesp (darbepoetin), Epogen (epoetin alfa), and Procrit (epoetin alfa)] (3/2007) http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm126485.htm.
93. Hadland BK, Longmore GD. Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms. J Clin Oncol 2009, 27(25):4217-4226. 10.1200/JCO.2008.21.6945, 19636005.
94. Bao B, Azmi AS, Ali S, Ahmad A, Li Y, Banerjee S, Kong D, Sarkar FH. The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. Biochim Biophys Acta 2012, 1826(2):272-296.
95. Jiang J, Tang YL, Liang XH. EMT: a new vision of hypoxia promoting cancer progression. Cancer Biol Ther 2011, 11(8):714-723. 10.4161/cbt.11.8.15274, 21389772.
96. Ho MY, Tang SJ, Chuang MJ, Cha TL, Li JY, Sun GH, Sun KH. TNF-alpha induces epithelial-mesenchymal transition of renal cell carcinoma cells via a GSK3beta-dependent mechanism. Mol Cancer Res 2012, 10(8):1109-1119. 10.1158/1541-7786.MCR-12-0160, 22707636.
97. Chuang MJ, Sun KH, Tang SJ, Deng MW, Wu YH, Sung JS, Cha TL, Sun GH. Tumor-derived tumor necrosis factor-alpha promotes progression and epithelial-mesenchymal transition in renal cell carcinoma cells. Cancer Sci 2008, 99(5):905-913. 10.1111/j.1349-7006.2008.00756.x, 18294286.
98. Sanghera KP, Mathalone N, Baigi R, Panov E, Wang D, Zhao X, Hsu H, Wang H, Tropepe V, Ward M, et al. The PI3K/Akt/mTOR pathway mediates retinal progenitor cell survival under hypoxic and superoxide stress. Mol Cell Neurosci 2011, 47(2):145-153. 10.1016/j.mcn.2011.03.010, 21463685.
99. Abhold E, Rahimy E, Wang-Rodriguez J, Blair KJ, Yu MA, Brumund KT, Weisman RA, Ongkeko WM. Recombinant human erythropoietin promotes the acquisition of a malignant phenotype in head and neck squamous cell carcinoma cell lines in vitro. BMC Res Notes 2011, 4:553. 10.1186/1756-0500-4-553, 3285115, 22188703.
100. Berdel WE, Oberberg D, Reufi B, Thiel E. Studies on the role of recombinant human erythropoietin in the growth regulation of human nonhematopoietic tumor cells in vitro. Ann Hematol 1991, 63(1):5-8. 10.1007/BF01714953, 1878424.